Soleo Health has been named the exclusive in-network specialty pharmacy for Qfitlia (fitusiran) by Sanofi, the first ...

Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United ...

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting factors.

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the third time. In September, J&J, via a subsidiary called Red River Talc, filed ...

The FDA granted approval to Sanofi’s fitusiran for the prophylactic treatment of people with hemophilia A or B with or without inhibitors. Fitusiran, which will be marketed by the name of ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis ... patients 12 years of age and older with hemophilia A or hemophilia B, with or without ...

The U.S. Food and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age ...

FDA Approves Qfitlia to Cut Bleeding Episodes in Patients With Hemophilia By Lori Solomon ... and Drug Administration has approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

The FDA has approved fitusiran, now named Qfitlia, for routine prophylaxis in patients aged 12 and older with hemophilia A or B, with or without inhibitors. Qfitlia offers less frequent administration ...